Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.
Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.
Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.
Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.